Меню
Набор скоро начнётся NCT07235397

Evaluating the Benefits of RSV Maternal Vaccination Using a Scottish National Dataset

— Наблюдательное Respiratory Syncytial Virus Infections

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: ABRYSVO.
Кому может быть актуально
Состояния в реестре: Respiratory Syncytial Virus Infections. Базовые параметры: 0 лет — 12 мес. · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Список центров уточняется — проверьте первичный протокол.
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Официальное название

Evaluating the Benefits Of RSV MaternaL vAccination Using a Scottish National Dataset.

Обзор

This study will use a retrospective cohort design and will be conducted within routinely collected national healthcare and statutory demographic datasets held by PHS and National Records of Scotland (NRS). As such, there will be no active enrollment of study participants, no direct contact with study participants, no collection of any primary data outside of the standard of care (SOC), and no requirement for informed consent. This study design was chosen due to several advantages, over other possible designs, including the ability to evaluate incidence of study outcomes in exposed and unexposed infants, ability to follow infants longitudinally to evaluate study outcomes through 12 months of age, and ability to evaluate all-cause outcomes. Study endpoints, including RSV-associated LRTD hospitalization and RSV-associated hospitalization, among infants born to ABRYSVO-vaccinated mothers (exposed group) will be compared with those among infants born to ABRYSVO-unvaccinated mothers (comparison group) initially from birth through 6 months of age, with later analysis from birth through 12 months as the infants reach this age threshold and their data become available.

Вмешательства

  • Биопрепарат ABRYSVO
    ABRYSVO

Первичные конечные точки

  • PCR-confirmed RSV-associated LRTD hospitalization occurring ≤180 days after birth (first episode) [Срок оценки: ≤180 days after birth]
Вторичные конечные точки (7)
  • PCR-confirmed RSV-associated hospitalization occurring ≤180 days after birth (first episode) [Срок оценки: ≤180 days after birth]
  • PCR-confirmed RSV-associated LRTD hospitalization occurring ≤180 days after birth (first episode) stratified by term/preterm status and by gestational age at vaccination [Срок оценки: ≤180 days after birth]
  • PCR-confirmed RSV-associated hospitalization occurring ≤180 days after birth (first episode) stratified by term/preterm status at delivery and by gestational age at vaccination [Срок оценки: ≤180 days after birth]
  • PCR-confirmed RSV-associated LRTD hospitalization occurring ≤360 days after birth (first episode) (by cumulative and by discrete age-intervals) [Срок оценки: ≤360 days after birth]
  • PCR-confirmed RSV-associated hospitalization occurring ≤360 days after birth (first episode) (by cumulative and by discrete age-intervals) [Срок оценки: ≤360 days after birth]
  • LRTI hospitalization (any cause) occurring ≤360 days after birth (first episode during the RSV season) (cumulative and by age-intervals) [Срок оценки: ≤360 days after birth]
  • ARI hospitalization (any cause) occurring ≤360 days after birth (first episode during the RSV season) (cumulative and by age-intervals) [Срок оценки: ≤360 days after birth]

Критерии участия

Infants must meet all inclusion criteria to be eligible for inclusion in the study:

  • Live birth in Scotland from 1st September 2024 to 28th February 2026
  • Gestational age at birth ≥28(0/7) weeks of gestation (earliest gestational age eligible for ABRYSVO vaccination)

Infants meeting any of the following criteria will not be included in the study:

  • Born to a mother who received any licensed or investigational RSV vaccine other than ABRYSVO at any time during pregnancy
  • Meets UK national guidelines for monoclonal antibody receipt

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Модель наблюдения
Когортное

Центры проведения

Список центров уточняется — проверьте первичный протокол.

Идентификаторы

NCT: NCT07235397 · C3671083

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗